<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001903'>Anaemia</z:hpo> is a common finding in patients with <z:mp ids='MP_0002055'>diabetes</z:mp>, particularly in those with overt <z:hpo ids='HP_0000112'>nephropathy</z:hpo> or <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In tertiary clinics, at least one outpatient in five with <z:mp ids='MP_0002055'>diabetes</z:mp> has <z:hpo ids='HP_0001903'>anaemia</z:hpo>, for whom it constitutes a significant additional burden </plain></SENT>
<SENT sid="2" pm="."><plain>DISCUSSION: <z:hpo ids='HP_0001903'>Anaemia</z:hpo> is associated with an increased risk of <z:e sem="disease" ids="C0271672" disease_type="Disease or Syndrome" abbrv="">diabetic complications</z:e> including <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, <z:hpo ids='HP_0000488'>retinopathy</z:hpo> and macrovascular disease </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001903'>Anaemia</z:hpo> may also be significant in determining the outcome of <z:hpo ids='HP_0001635'>heart failure</z:hpo> and <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced organ damage in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>While several factors contribute to the increased prevalence of <z:hpo ids='HP_0001903'>anaemia</z:hpo> in <z:mp ids='MP_0002055'>diabetes</z:mp>, the failure of the kidney to increase erythropoietin in response to falling <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> appears to be the dominant factor </plain></SENT>
<SENT sid="5" pm="."><plain>Although there is a clear rationale for correcting <z:hpo ids='HP_0001903'>anaemia</z:hpo> in people with <z:mp ids='MP_0002055'>diabetes</z:mp>, it remains to be established whether this will lead to improved outcomes </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, the balance of risks, costs, and benefits remains to be established in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>The Trial to Reduce Cardiovascular Events with Aranesp (darbepoetin alpha) Therapy (TREAT) is a randomised controlled trial designed to determine the impact of <z:hpo ids='HP_0001903'>anaemia</z:hpo> correction on mortality and non-fatal cardiovascular events in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and stage 3-4 <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: It is anticipated that TREAT will help to define the optimal approach to the management of <z:hpo ids='HP_0001903'>anaemia</z:hpo> in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>